BMJ  2006;333:1238 (16 December), doi:10.1136/bmj.39062.360289.DB

News

Sponsorship of patients' groups by drug companies should be made transparent

¹ Heidelberg

The first 150 words of the full text of this article appear below.

Drug companies are sponsoring more and more groups for patients in Germany to increase demand for their products, but many members remain unaware of their involvement, a study has found.

The firms are also advertising their products on what seem to be independent websites, despite laws that ban advertising prescription medicines to the public.

The study, by the Zentrum für Sozialpolitik of Bremen University, was commissioned by Germany's state health insurance companies and focused on the funding of groups for patients with chronic diseases, such as Alzheimer's disease and eczema.

At present, health insurance companies are the main sponsor of patients' groups, spending a total 28m (£19m; $37m) in 2005, but drug companies are increasingly moving into the area.

A quarter of patients' groups derive about a fifth of their income from pharmaceutical firms; another 5% derive as much as half from that source. All German patients' groups receive state . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article

Should patient groups accept money from drug companies? No

Barbara Mintzes
BMJ 2007 334: 935. [Extract] [Full Text] [PDF]